Loading...

Frank McCormick, PhD, FRS

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentHDF Comprehensive Cancer Ctr
Address1450 Third St
San Francisco CA 94158
Phone415-502-1710
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Frank McCormick, PhD, FRS, is a Professor in the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick’s group led to the identification of a CDK4 kinase inhibitor. Dr. McCormick's current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.

    Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 285 scientific publications and holds 20 issued patents. He also served as President, 2012-2013 for the American Association for Cancer Research (AACR). More recently, he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.


    Collapse Research 
    Collapse Research Activities and Funding
    Biodesy Delta System for San Francisco Bay Area Region
    NIH S10OD023482Mar 15, 2017 - Mar 14, 2018
    Role: Principal Investigator
    New Ways of Targeting K-Ras
    NIH/NCI R35CA197709Apr 1, 2016 - Mar 31, 2023
    Role: Principal Investigator
    Bay Area Cancer Target Discovery and Development Network
    NIH/NCI U01CA168370May 1, 2012 - Apr 30, 2017
    Role: Co-Principal Investigator
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - May 31, 2018
    Role: Co-Principal Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018 Apr 05; 173(2):321-337.e10. PMID: 29625050.
      View in: PubMed
    2. Yuan TL, Amzallag A, Bagni R, Yi M, Afghani S, Burgan W, Fer N, Strathern LA, Powell K, Smith B, Waters AM, Drubin D, Thomson T, Liao R, Greninger P, Stein GT, Murchie E, Cortez E, Egan RK, Procter L, Bess M, Cheng KT, Lee CS, Lee LC, Fellmann C, Stephens R, Luo J, Lowe SW, Benes CH, McCormick F. Differential Effector Engagement by Oncogenic KRAS. Cell Rep. 2018 Feb 13; 22(7):1889-1902. PMID: 29444439.
      View in: PubMed
    3. McCormick F. c-Raf in KRas Mutant Cancers: A Moving Target. Cancer Cell. 2018 Feb 12; 33(2):158-159. PMID: 29438690.
      View in: PubMed
    4. Kitagawa M, Liao PJ, Lee KH, Wong J, Shang SC, Minami N, Sampetrean O, Saya H, Lingyun D, Prabhu N, Diam GK, Sobota R, Larsson A, Nordlund P, McCormick F, Ghosh S, Epstein DM, Dymock BW, Lee SH. Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality. Nat Commun. 2017 Dec 19; 8(1):2200. PMID: 29259156.
      View in: PubMed
    5. Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL, McCormick F, McManus MT. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017 11 09; 551(7679):247-250. PMID: 29088702.
      View in: PubMed
    6. Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, Hobbs GA, Tessier-Cloutier B, Gillette WK, Bagni R, Whiteley GR, Hartley JL, McCormick F, Cox AD, Houghton PJ, Huntsman DG, Philips MR, Der CJ. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal. 2017 Sep 26; 10(498). PMID: 28951536.
      View in: PubMed
    7. Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017 Jun 29; 170(1):17-33. PMID: 28666118.
      View in: PubMed
    8. Novotny CJ, Hamilton GL, McCormick F, Shokat KM. Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras. ACS Chem Biol. 2017 Jul 21; 12(7):1956-1962. PMID: 28530791.
      View in: PubMed
    9. Stephens RM, Yi M, Kessing B, Nissley DV, McCormick F. Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes. Cancer Inform. 2017; 16:1176935117711944. PMID: 28634423.
      View in: PubMed
    10. Tetsu O, McCormick F. ETS-targeted therapy: can it substitute for MEK inhibitors? Clin Transl Med. 2017 Dec; 6(1):16. PMID: 28474232.
      View in: PubMed
    11. Wang SJ, Asthana S, van Zante A, Heaton CM, Phuchareon J, Stein L, Higuchi S, Kishimoto T, Chiu CY, Olshen AB, McCormick F, Tetsu O. Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient. Oral Oncol. 2017 Jun; 69:1-10. PMID: 28559012.
      View in: PubMed
    12. Ye X, Chan KC, Waters AM, Bess M, Harned A, Wei BR, Loncarek J, Luke BT, Orsburn BC, Hollinger BD, Stephens RM, Bagni R, Martinko A, Wells JA, Nissley DV, McCormick F, Whiteley G, Blonder J. Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface. Oncotarget. 2016 Dec 27; 7(52):86948-86971. PMID: 27894102.
      View in: PubMed
    13. Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH, Ghirlando R, Nissley DV, Esposito D, McCormick F, Stephen AG, Simanshu DK. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEd. Proc Natl Acad Sci U S A. 2016 11 01; 113(44):E6766-E6775. PMID: 27791178.
      View in: PubMed
    14. Dunzendorfer-Matt T, Mercado EL, Maly K, McCormick F, Scheffzek K. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation. Proc Natl Acad Sci U S A. 2016 07 05; 113(27):7497-502. PMID: 27313208; PMCID: PMC4941445.
    15. Stevenson DA, Schill L, Schoyer L, Andresen BS, Bakker A, Bayrak-Toydemir P, Burkitt-Wright E, Chatfield K, Elefteriou F, Elgersma Y, Fisher MJ, Franz D, Gelb BD, Goriely A, Gripp KW, Hardan AY, Keppler-Noreuil KM, Kerr B, Korf B, Leoni C, McCormick F, Plotkin SR, Rauen KA, Reilly K, Roberts A, Sandler A, Siegel D, Walsh K, Widemann BC. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. Am J Med Genet A. 2016 Aug; 170(8):1959-66. PMID: 27155140; PMCID: PMC4945362.
    16. McCormick F. K-Ras protein as a drug target. J Mol Med (Berl). 2016 Mar; 94(3):253-8. PMID: 26960760; PMCID: PMC4803814.
    17. Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F. Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy. 2016; 61(5):223-35. PMID: 26910730; PMCID: PMC4844777 [Available on 02/25/17].
    18. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD, Balmain A, McCormick F. K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling. Cell. 2015 Nov 19; 163(5):1237-1251. PMID: 26590425.
      View in: PubMed
    19. Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, Chertov O, Frank PH, Grose C, Jones JE, Meng Z, Perkins S, Van Q, Ghirlando R, Fivash M, Nissley DV, McCormick F, Holderfield M, Stephen AG. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. Sci Rep. 2015 Nov 02; 5:15916. PMID: 26522388; PMCID: PMC4629113.
    20. Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F. AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol Res. 2015 Dec; 102:132-7. PMID: 26453958.
      View in: PubMed
    21. Tetsu O, Phuchareon J, Eisele DW, McCormick F. ETS1 inactivation causes innate drug resistance to EGFR inhibitors. Mol Cell Oncol. 2016 Mar; 3(2):e1078924. PMID: 27308601; PMCID: PMC4905380.
    22. Phuchareon J, McCormick F, Eisele DW, Tetsu O. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A. 2015 Jul 21; 112(29):E3855-63. PMID: 26150526; PMCID: PMC4517222.
    23. Nan X, Tamgüney TM, Collisson EA, Lin LJ, Pitt C, Galeas J, Lewis S, Gray JW, McCormick F, Chu S. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A. 2015 Jun 30; 112(26):7996-8001. PMID: 26080442; PMCID: PMC4491781.
    24. Fujita-Sato S, Galeas J, Truitt M, Pitt C, Urisman A, Bandyopadhyay S, Ruggero D, McCormick F. Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. Cancer Res. 2015 Jul 15; 75(14):2851-62. PMID: 25977330; PMCID: PMC4506276.
    25. McCormick F. KRAS as a Therapeutic Target. Clin Cancer Res. 2015 Apr 15; 21(8):1797-801. PMID: 25878360; PMCID: PMC4407814.
    26. McCormick F. The potential of targeting Ras proteins in lung cancer. Expert Opin Ther Targets. 2015 Apr; 19(4):451-4. PMID: 25558943.
      View in: PubMed
    27. Tetsu O, Eisele DW, McCormick F. Resistance to EGFR-targeted therapy by Ets-1 inactivation. Cell Cycle. 2015; 14(20):3211-2. PMID: 26313421; PMCID: PMC4825599.
    28. Martins MM, Zhou AY, Corella A, Horiuchi D, Yau C, Rakshandehroo T, Gordan JD, Levin RS, Johnson J, Jascur J, Shales M, Sorrentino A, Cheah J, Clemons PA, Shamji AF, Schreiber SL, Krogan NJ, Shokat KM, McCormick F, Goga A, Bandyopadhyay S. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015 Feb; 5(2):154-67. PMID: 25501949; PMCID: PMC4407699.
    29. Phuchareon J, Overdevest JB, McCormick F, Eisele DW, van Zante A, Tetsu O. Fatty Acid binding protein 7 is a molecular marker in adenoid cystic carcinoma of the salivary glands: implications for clinical significance. Transl Oncol. 2014 Dec; 7(6):780-7. PMID: 25500088; PMCID: PMC4311037.
    30. Guinney J, Dienstmann R, Ferté C, Friend S, McCormick F. Social interactomes for enabling research communities. Cancer Discov. 2014 Nov; 4(11):1265-8. PMID: 25367949.
      View in: PubMed
    31. Phuchareon J, van Zante A, Overdevest JB, McCormick F, Eisele DW, Tetsu O. c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. Transl Oncol. 2014 Oct; 7(5):537-45. PMID: 25389449; PMCID: PMC4225653.
    32. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014 Aug 21; 8(4):1037-48. PMID: 25127139; PMCID: PMC4294625.
    33. Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014 Oct; 4(10):1182-1197. PMID: 25100204; PMCID: PMC4184972.
    34. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014 Jul; 14(7):455-67. PMID: 24957944; PMCID: PMC4250230.
    35. Nwachukwu BU, McCormick F, Schairer WW, Frank RM, Provencher MT, Roche MW. Unicompartmental knee arthroplasty versus high tibial osteotomy: United States practice patterns for the surgical treatment of unicompartmental arthritis. J Arthroplasty. 2014 Aug; 29(8):1586-9. PMID: 24814891.
      View in: PubMed
    36. Thai M, Graham NA, Braas D, Nehil M, Komisopoulou E, Kurdistani SK, McCormick F, Graeber TG, Christofk HR. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 2014 Apr 01; 19(4):694-701. PMID: 24703700; PMCID: PMC4294542.
    37. Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014 Mar 17; 25(3):272-81. PMID: 24651010.
      View in: PubMed
    38. Harris JD, Cvetanovich G, Erickson BJ, Abrams GD, Chahal J, Gupta AK, McCormick F, Bach BR. Current status of evidence-based sports medicine. Arthroscopy. 2014 Mar; 30(3):362-71. PMID: 24581261.
      View in: PubMed
    39. Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res. 2014 Apr 15; 74(8):2238-45. PMID: 24523442.
      View in: PubMed
    40. Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014; 9(2):e87220. PMID: 24504419; PMCID: PMC3913610.
    41. Abrams GD, Harris JD, Gupta AK, McCormick F, Bush-Joseph CA, Verma NN, Cole BJ, Bach BR. Functional Performance Testing After Anterior Cruciate Ligament Reconstruction: A Systematic Review. Orthop J Sports Med. 2014 Jan; 2(1):2325967113518305. PMID: 26535266; PMCID: PMC4555525.
    42. Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A. 2014 Mar; 164A(3):563-78. PMID: 24443315; PMCID: PMC4150212.
    43. Salt MB, Bandyopadhyay S, McCormick F. Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov. 2014 Feb; 4(2):186-99. PMID: 24302555.
      View in: PubMed
    44. Yuan TL, McCormick F. Killing tumors by keeping ras and PI3' kinase apart. Cancer Cell. 2013 Nov 11; 24(5):562-3. PMID: 24229705.
      View in: PubMed
    45. Nan X, Collisson EA, Lewis S, Huang J, Tamgüney TM, Liphardt JT, McCormick F, Gray JW, Chu S. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A. 2013 Nov 12; 110(46):18519-24. PMID: 24158481; PMCID: PMC3831949.
    46. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van 't Veer LJ, Polyak K, McCormick F, Gray JW. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013 Oct 14; 24(4):450-65. PMID: 24094812; PMCID: PMC3931310.
    47. Gupta AK, Chalmers PN, Rahman Z, Bruce B, Harris JD, McCormick F, Abrams GD, Nicholson GP. Reverse total shoulder arthroplasty in patients of varying body mass index. J Shoulder Elbow Surg. 2014 Jan; 23(1):35-42. PMID: 24090984.
      View in: PubMed
    48. Lyons J, Bastian BC, McCormick F. MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A. 2013 Aug 20; 110(34):13845-50. PMID: 23908401; PMCID: PMC3752210.
    49. Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell. 2013 May 13; 23(5):594-602. PMID: 23680146.
      View in: PubMed
    50. McCormick F, Cvetanovich GL, Kim JM, Harris JD, Gupta AK, Abrams GD, Romeo AA, Provencher MT. An assessment of the quality of rotator cuff randomized controlled trials: utilizing the Jadad score and CONSORT criteria. J Shoulder Elbow Surg. 2013 Sep; 22(9):1180-5. PMID: 23510746.
      View in: PubMed
    51. Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 2013 Jan; 3(1):112-23. PMID: 23103856.
      View in: PubMed
    52. Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernández H, Burlingame AL, McCormick F. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 2012 Jul 01; 26(13):1421-6. PMID: 22751498; PMCID: PMC3403010.
    53. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One. 2012; 7(5):e37431. PMID: 22662154; PMCID: PMC3360787.
    54. McCormick F. Cancer therapy based on oncogene addiction. J Surg Oncol. 2011 May 01; 103(6):464-7. PMID: 21480237.
      View in: PubMed
    55. Rauen KA, Banerjee A, Bishop WR, Lauchle JO, McCormick F, McMahon M, Melese T, Munster PN, Nadaf S, Packer RJ, Sebolt-Leopold J, Viskochil DH. Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet. 2011 May 15; 157C(2):136-46. PMID: 21495172; PMCID: PMC4145816.
    56. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011 Mar; 2(3):359-72. PMID: 21779505; PMCID: PMC3128641.
    57. McCormick F. Mutant onco-proteins as drug targets: successes, failures, and future prospects. Curr Opin Genet Dev. 2011 Feb; 21(1):29-33. PMID: 21236660.
      View in: PubMed
    58. Lee SH, McCormick F, Saya H. Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol. 2010 Dec 13; 191(6):1069-77. PMID: 21149564; PMCID: PMC3002031.
    59. Lyle C, McCormick F. Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J. 2010 Jul 08; 7:148. PMID: 20615244; PMCID: PMC2909962.
    60. Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell. 2010 Jun 15; 17(6):574-83. PMID: 20541702; PMCID: PMC2902369.
    61. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol. 2010 May; 7(5):251-65. PMID: 20351699.
      View in: PubMed
    62. Phan VT, Ding VW, Li F, Chalkley RJ, Burlingame A, McCormick F. The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans. Mol Cell Biol. 2010 May; 30(9):2264-79. PMID: 20160012; PMCID: PMC2863595.
    63. Kissil JL, Blakeley JO, Ferner RE, Huson SM, Kalamarides M, Mautner VF, McCormick F, Morrison H, Packer R, Ramesh V, Ratner N, Rauen KA, Stevenson DA, Hunter-Schaedle K, North K. What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A. 2010 Feb; 152A(2):269-83. PMID: 20082461; PMCID: PMC2818482.
    64. McCormick F. How blocking Raf activates the MAPK pathway. Pigment Cell Melanoma Res. 2010 Apr; 23(2):187-9. PMID: 20128874.
      View in: PubMed
    65. Murayama-Hosokawa S, Oda K, Nakagawa S, Ishikawa S, Yamamoto S, Shoji K, Ikeda Y, Uehara Y, Fukayama M, McCormick F, Yano T, Taketani Y, Aburatani H. Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. Oncogene. 2010 Apr 01; 29(13):1897-908. PMID: 20062086.
      View in: PubMed
    66. Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, Fagin JA, Yu B, Aoki Y, Neel BG, Balmain A, Drake RR, Nolan GP, Zenker M, Bollag G, Sebolt-Leopold J, Gibbs JB, Silva AJ, Patton EE, Viskochil DH, Kieran MW, Korf BR, Hagerman RJ, Packer RJ, Melese T. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. 2010 Jan; 152A(1):4-24. PMID: 20014119; PMCID: PMC4051786.
    67. Fan QW, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal. 2009 Jan 27; 2(55):ra4. PMID: 19176518; PMCID: PMC2793677.
    68. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009 Jan 15; 69(2):565-72. PMID: 19147570; PMCID: PMC2737189.
    69. Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. Ras signaling and therapies. Adv Cancer Res. 2009; 102:1-17. PMID: 19595305.
      View in: PubMed
    70. Lee SH, Sterling H, Burlingame A, McCormick F. Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev. 2008 Nov 01; 22(21):2926-31. PMID: 18981471; PMCID: PMC2577792.
    71. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 2008 Oct 01; 68(19):8127-36. PMID: 18829572.
      View in: PubMed
    72. Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW. DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res. 2008 Aug; 36(14):4689-98. PMID: 18628296; PMCID: PMC2504308.
    73. Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2009 Feb; 23(2):396-9. PMID: 18615105; PMCID: PMC3655797.
    74. Rauen KA, Hefner E, Carrillo K, Taylor J, Messier L, Aoki Y, Gripp KW, Matsubara Y, Proud VK, Hammond P, Allanson JE, Delrue MA, Axelrad ME, Lin AE, Doyle DA, Kerr B, Carey JC, McCormick F, Silva AJ, Kieran MW, Hinek A, Nguyen TT, Schoyer L. Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A. 2008 May 01; 146A(9):1205-17. PMID: 18412122.
      View in: PubMed
    75. Yeang CH, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008 Aug; 22(8):2605-22. PMID: 18434431.
      View in: PubMed
    76. Kitagawa M, Lee SH, McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell. 2008 Feb 01; 29(2):217-31. PMID: 18243116.
      View in: PubMed
    77. Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One. 2007 Dec 05; 2(12):e1279. PMID: 18060073; PMCID: PMC2093994.
    78. Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet. 2008 Feb 01; 17(3):419-30. PMID: 17981815.
      View in: PubMed
    79. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007 Sep 19; 99(18):1410-4. PMID: 17848677.
      View in: PubMed
    80. McCormick F. Success and failure on the ras pathway. Cancer Biol Ther. 2007 Oct; 6(10):1654-9. PMID: 18245956.
      View in: PubMed
    81. Iacovides DC, O'Shea CC, Oses-Prieto J, Burlingame A, McCormick F. Critical role for arginine methylation in adenovirus-infected cells. J Virol. 2007 Dec; 81(23):13209-17. PMID: 17686851; PMCID: PMC2169124.
    82. Ding VW, Lin LP, Chiang AL, McCormick F. Activation of p53 by Dishevelled independent of Wnt or planar polarity pathways. J Mol Med (Berl). 2007 Nov; 85(11):1281-9. PMID: 17593335.
      View in: PubMed
    83. Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O. A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One. 2006 Dec 27; 1:e128. PMID: 17205132; PMCID: PMC1762433.
    84. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 Dec; 10(6):515-27. PMID: 17157791; PMCID: PMC2730521.
    85. Lee SH, McCormick F. p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J. 2006 Sep 06; 25(17):4008-19. PMID: 16932749; PMCID: PMC1560370.
    86. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther. 2006 May; 6(5):697-708. PMID: 16759161.
      View in: PubMed
    87. Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell. 2006 Apr 21; 22(2):217-30. PMID: 16630891.
      View in: PubMed
    88. Rodriguez-Viciana P, McCormick F. Ras ubiquitination: coupling spatial sorting and signal transmission. Cancer Cell. 2006 Apr; 9(4):243-4. PMID: 16616329.
      View in: PubMed
    89. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006 Mar 03; 311(5765):1287-90. PMID: 16439621.
      View in: PubMed
    90. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res. 2006 Jan 15; 12(2):556-62. PMID: 16428500.
      View in: PubMed
    91. Rodriguez-Viciana P, McCormick F. Characterization of interactions between ras family GTPases and their effectors. Methods Enzymol. 2006; 407:187-94. PMID: 16757324.
      View in: PubMed
    92. You L, Kim J, He B, Xu Z, McCormick F, Jablons DM. Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect. 2006 Jan-Feb; 19(1):27-31. PMID: 16550254.
      View in: PubMed
    93. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005 Dec 01; 65(23):10669-73. PMID: 16322209.
      View in: PubMed
    94. McCormick F. Future prospects for oncolytic therapy. Oncogene. 2005 Nov 21; 24(52):7817-9. PMID: 16299540.
      View in: PubMed
    95. Mazieres J, You L, He B, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene. 2005 Aug 11; 24(34):5396-400. PMID: 16007226.
      View in: PubMed
    96. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 2005 Aug; 12(8):673-81. PMID: 15803147.
      View in: PubMed
    97. Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell. 2005 Aug; 8(2):111-8. PMID: 16098464.
      View in: PubMed
    98. O'Shea CC, Choi S, McCormick F, Stokoe D. Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle. 2005 Jul; 4(7):883-8. PMID: 15970698.
      View in: PubMed
    99. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. 2005 Jul; 8(1):61-74. PMID: 16023599.
      View in: PubMed
    100. Klein S, McCormick F, Levitzki A. Killing time for cancer cells. Nat Rev Cancer. 2005 07; 5(7):573-80. PMID: 15965492.
      View in: PubMed
    101. He B, Reguart N, You L, Mazieres J, Xu Z, Lee AY, Mikami I, McCormick F, Jablons DM. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene. 2005 Apr 21; 24(18):3054-8. PMID: 15735684.
      View in: PubMed
    102. O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, Shen J, McCormick F, Stokoe D. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J. 2005 Mar 23; 24(6):1211-21. PMID: 15775987; PMCID: PMC556401.
    103. Rodriguez-Viciana P, McCormick F. RalGDS comes of age. Cancer Cell. 2005 Mar; 7(3):205-6. PMID: 15766656.
      View in: PubMed
    104. He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res. 2005 Feb 01; 65(3):743-8. PMID: 15705870.
      View in: PubMed
    105. Lee SH, McCormick F. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl). 2005 Apr; 83(4):296-307. PMID: 15605273.
      View in: PubMed
    106. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec; 6(6):611-23. PMID: 15607965.
      View in: PubMed
    107. Brandts CH, Bilanges B, Hare G, McCormick F, Stokoe D. Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells. J Biol Chem. 2005 Jan 21; 280(3):2012-9. PMID: 15542603.
      View in: PubMed
    108. Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J. Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004 Oct 13; 3:29. PMID: 15482598; PMCID: PMC524523.
    109. Reguart N, He B, Xu Z, You L, Lee AY, Mazieres J, Mikami I, Batra S, Rosell R, McCormick F, Jablons DM. Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun. 2004 Oct 08; 323(1):229-34. PMID: 15351726.
      View in: PubMed
    110. Moule MG, Collins CH, McCormick F, Fried M. Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14063-6. PMID: 15383668; PMCID: PMC521121.
    111. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene. 2004 Aug 26; 23(39):6672-6. PMID: 15221014.
      View in: PubMed
    112. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F, Jablons DM. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004 Aug 12; 23(36):6170-4. PMID: 15208662.
      View in: PubMed
    113. You L, He B, Xu Z, Uematsu K, Mazieres J, Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, McCormick F, Jablons DM. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res. 2004 Aug 01; 64(15):5385-9. PMID: 15289346.
      View in: PubMed
    114. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res. 2004 Jul 15; 64(14):4717-20. PMID: 15256437.
      View in: PubMed
    115. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol. 2004 Jun; 24(11):4943-54. PMID: 15143186; PMCID: PMC416418.
    116. You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, Jablons DM. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res. 2004 May 15; 64(10):3474-8. PMID: 15150100.
      View in: PubMed
    117. McCormick F. Cancer: survival pathways meet their end. Nature. 2004 Mar 18; 428(6980):267-9. PMID: 15029179.
      View in: PubMed
    118. You L, He B, Xu Z, McCormick F, Jablons DM. Future directions: oncolytic viruses. Clin Lung Cancer. 2004 Jan; 5(4):226-30. PMID: 14967074.
      View in: PubMed
    119. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F, Jablons DM. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia. 2004 Jan-Feb; 6(1):7-14. PMID: 15068666; PMCID: PMC1508626.
    120. Timmerman LA, Grego-Bessa J, Raya A, Bertrán E, Pérez-Pomares JM, Díez J, Aranda S, Palomo S, McCormick F, Izpisúa-Belmonte JC, de la Pompa JL. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004 Jan 01; 18(1):99-115. PMID: 14701881; PMCID: PMC314285.
    121. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003 Nov 25; 100(24):14133-8. PMID: 14617776; PMCID: PMC283558.
    122. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003 Oct 16; 22(46):7218-21. PMID: 14562050.
      View in: PubMed
    123. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003 Aug; 34(4):369-76. PMID: 12923544.
      View in: PubMed
    124. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, Peterlin BM, McCormick F, Jablons DM. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003 Aug 01; 63(15):4547-51. PMID: 12907630.
      View in: PubMed
    125. McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S157-60. PMID: 14508094.
      View in: PubMed
    126. Jensen RH, Tiirikainen M, You L, Ginzinger D, He B, Uematsu K, Xu Z, Treseler P, McCormick F, Jablons DM. Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res. 2003 May-Jun; 23(3B):2281-9. PMID: 12894504.
      View in: PubMed
    127. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003 May 01; 63(9):2088-95. PMID: 12727824.
      View in: PubMed
    128. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 2003 Mar; 3(3):233-45. PMID: 12676582.
      View in: PubMed
    129. He B, You L, Uematsu K, Matsangou M, Xu Z, He M, McCormick F, Jablons DM. Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun. 2003 Feb 07; 301(2):386-91. PMID: 12565872.
      View in: PubMed
    130. Gump J, Stokoe D, McCormick F. Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem. 2003 Feb 28; 278(9):6619-22. PMID: 12529334.
      View in: PubMed
    131. Yang CT, You L, Lin YC, Lin CL, Mccormick F, Jablons DM. A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res. 2003 Jan-Feb; 23(1A):33-8. PMID: 12680192.
      View in: PubMed
    132. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002 Aug; 2(2):103-12. PMID: 12204530.
      View in: PubMed
    133. Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V, Schmitt LD, McCormick F. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res. 2002 Jul 01; 62(13):3812-8. PMID: 12097294.
      View in: PubMed
    134. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther. 2002 Jul; 1(9):687-94. PMID: 12479365.
      View in: PubMed
    135. Sabbatini P, McCormick F. MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol. 2002 Jul; 21(7):519-25. PMID: 12162806.
      View in: PubMed
    136. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, Hermiston T, Giedlin M, McCormick F, Fattaey A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell. 2002 May; 1(4):325-37. PMID: 12086848.
      View in: PubMed
    137. Biederer C, Ries S, Brandts CH, McCormick F. Replication-selective viruses for cancer therapy. J Mol Med (Berl). 2002 Mar; 80(3):163-75. PMID: 11894142.
      View in: PubMed
    Frank's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _